Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study-Reference-Cited by-同舟云学术

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Published:2020-05-12 Issue:16 Volume:26 Page:4268-4279
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Lampert Erika J.^ORCID,Zimmer Alexandra^ORCID,Padget Michelle,Cimino-Mathews Ashley^ORCID,Nair Jayakumar R.,Liu Yingmiao,Swisher Elizabeth M.^ORCID,Hodge James W.^ORCID,Nixon Andrew B.^ORCID,Nichols Erin,Bagheri Mohammad H.^ORCID,Levy Elliott,Radke Marc R.,Lipkowitz Stanley^ORCID,Annunziata Christina M.,Taube Janis M.,Steinberg Seth M.,Lee Jung-Min

Funder

NCICCRCCR

National Ovarian Cancer Coalition

DDCF

NCINIHNIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

2. Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial;2024-08-30

3. Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells;Cancer Cell International;2024-08-12

4. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer;Frontiers in Oncology;2024-08-02

5. Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer;JOVE-J VIS EXP;2024